Verition Fund Management LLC Makes New Investment in Metagenomi, Inc. (NASDAQ:MGX)

Verition Fund Management LLC bought a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 37,675 shares of the company’s stock, valued at approximately $82,000. Verition Fund Management LLC owned about 0.10% of Metagenomi as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. Rhumbline Advisers bought a new stake in shares of Metagenomi during the second quarter valued at approximately $26,000. BNP Paribas Financial Markets raised its position in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Metagenomi in the 2nd quarter worth $66,000. Green Alpha Advisors LLC bought a new position in shares of Metagenomi during the 3rd quarter worth $69,000. Finally, Resolute Advisors LLC increased its stake in shares of Metagenomi by 165.0% during the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock valued at $108,000 after buying an additional 16,500 shares during the period.

Wall Street Analyst Weigh In

MGX has been the subject of a number of research reports. HC Wainwright upped their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Trading Up 9.2 %

NASDAQ:MGX opened at $3.39 on Wednesday. Metagenomi, Inc. has a 12 month low of $1.61 and a 12 month high of $12.74. The firm has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $3.21.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.